Across TCGA pan-cancer cohorts, PRELID3BP6 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated PRELID3BP6 data layer.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PRELID3BP6 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRELID3BP6 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCS show a favorable association.
KIRP, HNSC, and THCA are the cancer types where PRELID3BP6 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.